Vabysmo 120mg/ml Injection

Vabysmo is injected directly into the eye at baseline and then monthly for the first 4 to 6 months depending on the condition. Each injection delivers 6 mg (0.05 mL of 120 mg/mL solution). After initial treatment, the injection frequency may be adjusted to every 8 to 12 weeks based on your clinical response and tolerability.

Common side effects are cataracts (15%) and conjunctival hemorrhage (8%). Other effects include floaters, eye pain, and increased eye pressure. Rare serious effects include eye infection (endophthalmitis), retinal detachment, vascular occlusion, and systemic thromboembolic events. Report vision changes, severe eye pain, redness, or flashing lights immediately to your eye doctor.

Do not use Vabysmo if you have active eye infection or intraocular inflammation. Avoid in cases of documented allergy to faricimab or excipients. Discuss cardiovascular disease with your doctor as it increases thromboembolic risk from VEGF inhibition. Monitor blood pressure regularly. Inform your ophthalmologist about all medications and health conditions.

Your ophthalmologist injects 6 mg directly into the eye using sterile technique. Watch carefully for endophthalmitis symptoms (pain, redness, vision loss) for 60 minutes after injection. Transient eye pressure increase may occur within 60 minutes. Report any severe eye pain or sudden vision loss immediately. Some floaters or mild irritation is normal after injection.

Store Vabysmo refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze the medication. Keep in the original carton protected from light. Vabysmo may remain at room temperature (20-25°C) for up to 24 hours before injection if needed. Each pre-filled syringe is single-use only for a single eye injection.